Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Evaluating the benefits of selective CDK4 inhibition in HR+/HER2- breast cancer

Antonio Giordano • 31 May 2024
ASCO 2024
Breast Cancer PF-07220060

Antonio Giordano, MD, PhD, Dana Farber Cancer Institute, Boston, MA, comments on the potential advantages of PF-07220060, a selective CDK4 inhibitor, in patients with HR+/HER2- breast cancer. Specifically targeting CDK4 can increase cell cycle inhibition in cancer, reducing toxicity and adverse events such as neutropenia, thrombocytopenia, nausea and vomiting. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Pfizer; Pfizer

More from Antonio Giordano

Phase III trial of PF-07220060 and fulvestrant in HR+/HER2- breast cancer
1:02
Phase III trial of PF-07220060 and fulvestrant in HR+/HER2- breast cancer
Antonio Giordano • 31 May 2024
The future of enfortumab vedotin in triple-negative and HR+/HER2- breast cancer
0:33
The future of enfortumab vedotin in triple-negative and HR+/HER2- breast cancer
Antonio Giordano • 31 May 2024
EV-202: enfortumab vedotin in pretreated HR+/HER2- breast cancer and TNBC
1:25
EV-202: enfortumab vedotin in pretreated HR+/HER2- breast cancer and TNBC
Antonio Giordano • 31 May 2024
Updated safety findings of PF-07220060 and endocrine therapy in HR+/HER2- breast cancer
1:20
Updated safety findings of PF-07220060 and endocrine therapy in HR+/HER2- breast cancer
Antonio Giordano • 31 May 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals